CLINICAL DESIGN TECHNOLOGIES LTD

Registered office: 82 St John Street, London, EC1M 4JN

(the “Company”)

On 30 April 2026 the Company entered administration. It is anticipated that there will be insufficient funds to enable a distribution to be made to unsecured creditors and that, in due course, the administrators will place the Company into insolvent liquidation.

We, Daniel John Bee and Oliver Blackwell, were each a director of the Company on the date it entered administration.

Section 216(3) of the Insolvency Act 1986 lists the activities that a director of a company that has gone into insolvent liquidation may not undertake unless the court gives permission or there is an exception in the Insolvency Rules made under the Insolvency Act 1986 (including the exceptions in Part 22 of the Insolvency (England and Wales) Rules 2016). These activities are:

(a) acting as a director of another company that is known by a name which is either the same as a name used by the company in insolvent liquidation in the 12 months before it entered liquidation or is so similar as to suggest an association with that company;

(b) directly or indirectly being concerned or taking part in the promotion, formation or management of any such company; or

(c) directly or indirectly being concerned in the carrying on of a business otherwise than through a company under a name of the kind mentioned in (a) above.

This notice is given under rule 22.4 of the Insolvency (England and Wales) Rules 2016. The rule applies where the business of a company which is in, or may go into, insolvent liquidation is, or is to be, carried on otherwise than by that company, with the involvement of a director of that company and under the same or a similar name to that of that company. The Company is in administration and is expected to go into insolvent liquidation; the whole or substantially the whole of the business of the Company was sold to another company, and that business is being carried on by that company.

The whole or substantially the whole of the business of the Company was sold to Clinical Design Technologies Group Ltd (registered number 17153624) on 19 May 2026. The notice is given within 28 days of that date of sale.

The purpose of giving this notice is to permit the directors named below to act in these circumstances when the Company enters insolvent liquidation, without committing a criminal offence under section 216 and, in the case of the carrying on of the business through another company, without being personally liable for that company’s debts.

Notice may be given where the person giving the notice is already a director of a company which proposes to adopt a prohibited name.

TAKE NOTICE that we are acting and intend to continue to act in all or any of the ways specified in section 216(3) of the Insolvency Act 1986 in connection with, or for the purpose of, the carrying on of the whole or substantially the whole of the business of the Company under the name “Clinical Design Technologies Group Ltd”, now registered with company number 17153624 (such name being the same as, or so similar as to suggest an association with, the name of the Company).

Without this notice, we would not be permitted, when the Company enters insolvent liquidation, to undertake these activities without the leave of the court or the application of an exception created by Rules made under the Insolvency Act 1986.

The breach of the prohibition created by section 216 of the Insolvency Act 1986 is a criminal offence and may also result in personal liability for the relevant company’s debts.